Effectiveness of Alendronate in Treating Osteoporosis and Its Relationship with N740N Polymorphism of Low-density Lipoprotein Receptor Related Protein 5 Gene

傅文贞,柯耀华,汪纯,章振林

DOI: https://doi.org/10.3969/j.issn.1007-9572.2012.08.052

2012-01-01

Chinese General Practice

Abstract:Objective To investigate whether the change of bone mineral density(BMD) after one-year alendronate treatment in postmenopausal patients with osteoporosis associates with the N740N polymorphism of low density lipoprotein receptor related protein 5(LRP5) gene and determine the correlation between genotypes and the therapeutic effect.Methods Totally 67 postmenopausal osteoporotic patients aged(64.2±7.7) years were recruited.Each patient took oral alendronate(Forsamax) 70 mg weekly and caltrate 600 mg daily for 12 months.Bone mass density was measured at lumbar spine 2-4 and left hip sites before and after treatment.PCR-RELP was performed for the N740N polymorphism of low density lipoprotein receptor related protein 5(LRP5) gene.Results One-year therapy was accomplished in 63 patients.Compared with the baseline level,the post-treatment BMD increased significantly at all sites:BMD increased by(4.05±3.39)% at the lumer spine 2~4,by(1.05±2.63)% at femoral neck,by(2.00±2.89)% at the torch,by(2.17±2.62)% at inter-torch,and by(1.79±2.29)% at total hip(allP0.01).In all the 63 patients,the frequencies of CC and CT genotypes were 65.1% and 34.9%.TT genotype was not found.The distribution followed the Hardy-Weinberg equilibrium.For the greater trochanter bone density change percentage after treatment,CC genotype increased by(2.53± 3.77)% and CT genotype by(6.35± 6.43)%;similarly,for the total hip bone mineral density change percentage,CC genotype increased by(1.93± 2.33)% and CT genotype by(3.79± 4.15)%.The two genotypes were significantly associated with the percentage of BMD at lumer spine L 2~4,femoral neck,and inter-torch.Conclusion The BMD increases more remarkably at lumbar spine than at hip sites in postmenopausal osteoporotic Chinese women after one-year alendronate therapy.CT gene type shows a better correlation with alendronate treatment than CC gene type,which should be further validated.